Literature DB >> 15238074

Interleukin-2, but not interleukin-15, is required to terminate experimentally induced clonal T-cell anergy.

S Bendiksen1, O P Rekvig.   

Abstract

It has been demonstrated that T cells stimulated with nucleosome-polyomavirus T-antigen (self-nonself) complexes, but not nucleosomes, activate autoimmune nucleosome-specific T cells. As these cells may be naïve, such observations do not show that anergic T cells are reactivated. To understand the regulation of autoimmunity, this is important to assess, and this is the focus of this study. T-cell anergy was induced by antigen stimulation in the presence of antibodies to the costimulatory molecules CD80/CD86. Requirements for the reactivation of anergic T cells were analysed by the ability of antigen and interleukin-2 (IL-2) or IL-15 to increase T-cell proliferation and IL-2 transcription. Data demonstrate that stimulation of T cells with T-antigen and anti-CD80/86 antibodies promotes long-lasting clonal T-cell anergy. While T-antigen did not reactivate anergic T cells, proliferation and upregulation of IL-2 gene transcription was initiated by stimulation with antigen, costimulation and IL-2 added to the cultures. Proliferation per se was not sufficient to promote the reactivation of anergic T cells, as both IL-2 and IL-15 induced proliferation, while antigen and IL-2, but not IL-15, upregulated IL-2 mRNA levels. These data demonstrate that the innate immune system and IL-2 are central to the initiation and termination of T-cell anergy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15238074     DOI: 10.1111/j.0300-9475.2004.01446.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  3 in total

Review 1.  Impact of infection on transplantation tolerance.

Authors:  Shuangjin Yu; Chang Su; Xunrong Luo
Journal:  Immunol Rev       Date:  2019-09-19       Impact factor: 12.988

2.  IL-2 signaling prevents T cell anergy by inhibiting the expression of anergy-inducing genes.

Authors:  Myrianne Duré; Fernando Macian
Journal:  Mol Immunol       Date:  2008-11-05       Impact factor: 4.407

3.  Local therapy of cancer with free IL-2.

Authors:  Willem Den Otter; John J L Jacobs; Jan J Battermann; Gerrit Jan Hordijk; Zachary Krastev; Ekaterina V Moiseeva; Rachel J E Stewart; Paul G P M Ziekman; Jan Willem Koten
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.